Celgene sues Dr Reddy’s over Pomalyst generic

Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories (DRL) to halt its plan to produce and market generic versions of Pomalyst (pomalidomide)—Celgene’s multiple myeloma treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Celgene sues Dr Reddy’s over Pomalyst generic

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features